Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04848584 · ClinicalTrials.gov registry record
Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1
- Enrollment target
NCT04848584 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1 participants.
The verdict
NCT04848584 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a retrospective cohort design. VE estimates by various strata and strain type will be conducted.
Interventions
- BIOLOGICAL Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
- BIOLOGICAL BNT162b2 BA.4/5 bivalent
- BIOLOGICAL XBB.1.5-adapted vaccinated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2025-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04848584
The ClinicalTrials.gov registry entry for NCT04848584 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine is the first listed.
NCT04848584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04848584 about?
NCT04848584 is a clinical study titled "Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California". The primary objective of this study is to determine the vaccine effectiveness of 2 doses of Pfizer-BioNTech BNT162b2 vaccine against COVID-19-associated hospitalization. There will be a large retrospective database study using two parallel study designs: a test-negative case-control design and a ret...
What is the current status of trial NCT04848584?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2021-05-15. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT04848584?
The interventions under investigation include: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine (BIOLOGICAL), BNT162b2 BA.4/5 bivalent (BIOLOGICAL), XBB.1.5-adapted vaccinated (BIOLOGICAL).
Who is sponsoring clinical trial NCT04848584?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.